Cancers, Vol. 11, Pages 424: Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome

Conclusion: Our analysis supports treating GIST patients with neoadjuvant imatinib, which demonstrated favorable long-term results of combined therapy. However, careful monitoring of complications is necessary. The optimal duration of neoadjuvant imatinib use before surgical intervention is, on average, 6.1 months.

Source: Cancers - March 24, 2019 Category: Cancer & Oncology Authors: Shang-Yu Wang Chiao-En Wu Chun-Chi Lai Jen-Shi Chen Chun-Yi Tsai Chi-Tung Cheng Ta-Sen Yeh Chun-Nan Yeh Tags: Article Source Type: research